Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

Conditions:Parkinsons Disease, Cardiology, Cardiology, Neurology
Therapuetic Areas:Cardiology / Vascular Diseases, Neurology
Age Range:18 - 85
Start Date:August 23, 2018
End Date:August 2019
Contact:William Ondo, MD

Use our guide to learn which trials are right for you!

Evaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus Placebo

This is a double blind placebo controlled trial in Parkinson's disease (PD) patients with
neurogenic orthostatic hypotension (NOH). Investigators hypothesize that the study drug
(droxidopa) may improve cerebral perfusion more robustly than systemic BP, possibly by direct
action within the CNS vasculature. This study is designed to determine if droxidopa improves
cerebral perfusion measures in PD patients with NOH, in addition to peripheral BP measures
and subjective responses.

1. This is a double blind placebo controlled trial in PD patients with NOH. The controlled
portion consists of two visits (baseline and week 4) and a phone call (week 2). An open
label extension will include a phone call (week 6) and a final visit (week 8). Subjects
will undergo a baseline assessment including continuous tilt table (10 minutes supine /
30 minutes at 70o / 10 minute supine) measurements of arteriole BP. Assessment will be
done in the "on" state 1-3 hours after last dose and 1-3 hours after last meal. During
both supine and standing positions, subjects will undergo a quantified transcranial
cerebral ultrasound of the middle cerebral artery. A secondary analysis of the posterior
circulation (basilar artery) will also be done when technically possible. An experienced
technician will use a Spencer ST-3 Transcranial Doppler and MHz frequency probes
(Spencer Technologies, Redmond WA), with ability to display all data in real time with
M-mode and spectral waveform, depth of sample volume, size of sample volume, peak
systolic and end diastolic velocities, pulsatility index and frequency of transducer.
Cerebral oxygenation will be assessed throughout the tilt table with an FORE-SIGHT ELITE
Oximetry System (CASMED) with FORE-SIGHT ELITE large advanced sensor. Mean/Max/Min vales
will be analyzed. The tilt table BP and HR monitor with autonomic function will be
recorded with a Task Force monitor from CNsystem. Subjective assessments will be done
prior to the tilt table and will include demographics, general medical history, UPDRS,
and the orthostatic hypotension questionnaire, and some gait analysis. We will also
query their subjective "light headedness" throughout the tilt table test to determine
for objective correlates.

2. Subjects will be titrated with droxidopa or matching placebo over two weeks using
current guidelines. The dose will be held constant for the final two weeks and taken on
the day of the week 4 visit. After a safety and dose determination call at two weeks,
subjects will return at 4 weeks for an identical evaluation, along with clinical global
impressions of change.

3. All subjects will be allowed into a 4 week open label extension. They will start
titration at 100 mg droxidopa TID but can titrate up daily if preferred. After a safety
call (week 6) they will return for a final tilt table/ultrasound perfusion
study/oximetry study and subjective questionnaires. The patients will be provided two
additional weeks medication to ensure a safe transition to purchased droxidopa if

Inclusion Criteria:

- Idiopathic Parkinson's disease patients with orthostatic hypotension (Systolic Blood
Pressure drop of > 20 mm hg or Diastolic Blood Pressure drop of >10 mm hg measured at
some point) within a month of inclusion.

Exclusion Criteria:

- Age >85

- Concurrent use of Midodrine

- Medical conditions that in the opinion of the investigator, might not allow for same
completion of the study i.e. unstable angina, neoplasm, etc
We found this trial at
6550 Fannin St
Houston, Texas 77030
(713) 790-3311
Phone: 346-238-9068
Houston Methodist Hospital Houston Methodist is comprised of a leading academic medical center in the...
Houston, TX
Click here to add this to my saved trials